Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – C-o-group doai
Reexamination Certificate
2000-07-14
2003-02-18
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C-o-group doai
C514S733000, C514S734000, C424S401000, C424S070100
Reexamination Certificate
active
06521669
ABSTRACT:
CROSS-REFERENCE TO PRIORITY APPLICATION
This application claims priority under 35 U.S.C. §119 of FR-99/09267, filed Jul. 16, 1999, hereby expressly incorporated by reference.
BACKGROUND OF THE INVENTION
1. Technical Field of the Invention
The present invention relates to the administration of at least one hydroxystilbene compound, or composition comprised thereof, to an individual subject in need of such treatment, to reduce or even inhibit the glycation of proteins, particularly the proteins of the skin and/or of the structures associated therewith.
2. Description of the Prior Art
Glycation is a non-enzymatic process involving a saccharide (glucose or ribose) which reacts according to the Maillard reaction with an amino group of an amino acid residue (for example such as lysine), particularly an amino acid residue of a protein, to form a Schiff's base. This Schiff's base, after undergoing an Amadori molecular rearrangement, can lead, by a series of reactions, to bridging, particularly intramolecular bridging such as, for example, of pentosidine type.
This phenomenon increases uniformly with age. It is characterized by the appearance of glycation products whose content increases uniformly as a function of age. The glycation products are, for example, pyrraline, carboxymethyllysine, pentosidine, crossline, N
&egr;
(2-carboxyethyl)lysine (CEL), glyoxallysine dimer (GOLD), methylglyoxallysine dimer (MOLD), 3DG-ARG imidazolone, versperlysines A, B and C, threosidine or the advanced glycosylation end products (or AGEs).
The glycation of proteins is thus a universal phenomenon, which is well known to occur in the skin, particularly in its dermal component, but which also occurs in the structures associated therewith such as the nails or the hair, particularly on keratins and more generally in any protein system provided that the conditions required for glycation are satisfied.
Human skin consists of two components, namely, a superficial component, the epidermis, and a deep component, the dermis.
Natural human skin is principally composed of three types of cell: the keratinocytes, which constitute the vast majority, the melanocytes and the Langerhans cells. Each of these cell types contributes, by virtue of its intrinsic functions, towards the essential role played in the body by the skin.
The dermis provides the epidermis with a solid support. It is also the nourishing factor of the epidermis. It consists principally of fibroblasts and of an extracellular matrix itself composed of different extracellular proteins, among which are, in particular, collagen fibers, elastin and various glycoproteins This assembly of extracellular components is synthesized by the fibroblasts. Leukocytes, mastocytes and tissue macrophages are also found in the dermis. Finally, the dermis contains blood vessels and nerve fibers.
Taking account of their activity in the synthesis of the extracellular matrix proteins (proteoglycans, collagen fibers and other structural glycoproteins), the fibroblasts are the principal factors involved in the structural development of the dermis.
The collagen fibers provide the dermis with solidity. They are very strong but are sensitive to certain enzymes generally known as collagenases. In the dermis, the collagen fibers consist of fibrils bonded together, thus forming more than ten different types of structure. The structure of the dermis is essentially due to the overlapping of the packed collagen fibers. The collagen fibers contribute in respect of the tonicity of the skin. The collagen fibers are regularly renewed, but this renewal decreases with age, thus promoting, especially, a thinning of the dermis. It is also accepted that extrinsic factors such as ultraviolet radiation, tobacco or certain treatments (retinoic acid and derivatives, glucocorticoids, vitamin D and derivatives, for example) also have an effect on the skin and on its collagen level.
As regards the dermal component of the skin, glycation intervenes mainly in the dermis, on the collagen fibers, according to the process described above. The glycation of collagen increases uniformly with age, resulting in a uniform increase in the content of glycation products in the skin.
Without wishing to be bound to any particular theory in respect of aging of the skin, it should be noted that other modifications of collagen which might also be a consequence of glycation, such as a reduction in heat-denaturation, an increase in the resistance to enzymatic digestion and an increase in intermolecular bridges, have been demonstrated in the course of aging of the skin (Tanaka S. et al., 1988,
J. Mol. Biol
., 203, 495-505; Takahashi M. et al., 1995
, Analytical Biochemistry
, 232, 158-162). Furthermore, modifications due to the glycation of certain constituents of the basal membrane such as collagen IV, laminin and fibronectin have been demonstrated (Tarsio JF. et al., 1985
, Diabetes
, 34, 477-484; Tarsio JF. et al., 1988
, Diabetes
, 37, 532-539; Sternberg M. et al., 1995, C.R.
Soc. Biol
., 189, 967-985).
Thus, it is understood that in the course of aging of the skin, the physicochemical properties of collagen modify and this collagen becomes more difficult to dissolve and degrade.
Thus, one of the components of aged skin clearly appears to be glycated collagen.
It is very well known to this art that the skin results from a close combination between at least two components of which it is composed, namely, the epidermis and the dermis. The interactions between the dermis and the epidermis are such that it is reasonable to expect that a modification of one may have consequences on the other. It may be suspected that aging of the dermis, in particular with its glycation phenomena will inevitably have consequences on the epidermis with which is associated. In the course of aging of the skin, the glycation of collagen should result in modifications of the epidermis which are necessarily implicated in aging of the epidermis.
Thus, if the glycation of dermal proteins, particularly collagen, elicits nothing more than harmful consequences on the skin, similar consequences are to be expected of the glycation of the proteins in the structures associated with the skin such as, for example, the nails and/or the hair and, indeed, of any protein system.
It will thus be appreciated that need continues to exist for active agents/species which reduce or even inhibit the phenomenon of glycation of proteins.
SUMMARY OF THE INVENTION
It has now surprisingly and unexpectedly been determined that the hydroxystilbenes elicit the effect of reducing or even inhibiting the phenomenon of glycation of proteins.
Briefly, the present invention features the administration to an individual subject in need of such treatment, of an effective amount of at least one hydroxystilbene, or composition comprised thereof, to reduce or even inhibit the glycation of proteins, particularly the glycation of proteins of the skin and/or of the structures associated therewith.
This invention thus features a cosmetic/dermatological regime/regimen, comprising administering to an individual subject in need of such treatment, an effective amount of at least one hydroxystilbene, or composition comprised thereof, to reduce or even inhibit the glycation of dermal proteins, for example collagen, and/or the nails, and/or the hair, for example the keratins.
The present invention also features administration of an effective amount of at least one hydroxystilbene, or composition comprised thereof, to preventively and/or curatively treat the signs of aging of the skin or of its associated structures, which are implicated in glycation.
DETAILED DESCRIPTION OF BEST MODE AND SPECIFIC/PREFERRED EMBODIMENTS OF THE INVENTION
More particularly according to the present invention, the preferred hydroxystilbenes are compounds having the structural formula (I):
in which n is an integer ranging from 0 to 4, inclusive and m is an integer ranging from 0 to 5, inclusive. These compounds can be in a cis- or trans-form.
According to the invention, by the term “hydroxystilbene” are inten
Breton Lionel
Liviero Christel
Pageon Hervé
Burns Doane Swecker & Mathis L.L.P.
Padmanabhan Sreeni
Societe L'Oreal S.A.
Willis Michael A.
LandOfFree
Hydroxystilbene compounds for reducing/inhibiting protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydroxystilbene compounds for reducing/inhibiting protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydroxystilbene compounds for reducing/inhibiting protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3135940